User:Betsy Johns/Sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 29: Line 29:
[[Image:GDAT_MECH_DRAWING.png|1000 px|center|thumb|'''Figure 2: Active Site Mechanism Overview''' Modeled is the active site of DGAT (shown in teal) with its catalytic Histidine (His415), Oleoyl CoA (shown in pink), and a general diacylglycerol (DAG, shown in yellow). DAG enters the active site of DGAT through its lateral gate while the catalytic His415 flips from the cytosolic side to the lumenal side, in order for the channel opening located on the cytosolic side of DGAT to widen enough to accommodate the Oleoyl-CoA. The Oleoyl CoA then enters the active site through the channel opening located on the cytosolic side of DGAT. When the Oleoyl-CoA and DAG are within close proximity in the active site, the catalytic His415 catalyzes the reaction. The CoA head group leaves back through the channel located on the cytosolic side, while the product triacylglyceride leaves back through the lateral gate.]]
[[Image:GDAT_MECH_DRAWING.png|1000 px|center|thumb|'''Figure 2: Active Site Mechanism Overview''' Modeled is the active site of DGAT (shown in teal) with its catalytic Histidine (His415), Oleoyl CoA (shown in pink), and a general diacylglycerol (DAG, shown in yellow). DAG enters the active site of DGAT through its lateral gate while the catalytic His415 flips from the cytosolic side to the lumenal side, in order for the channel opening located on the cytosolic side of DGAT to widen enough to accommodate the Oleoyl-CoA. The Oleoyl CoA then enters the active site through the channel opening located on the cytosolic side of DGAT. When the Oleoyl-CoA and DAG are within close proximity in the active site, the catalytic His415 catalyzes the reaction. The CoA head group leaves back through the channel located on the cytosolic side, while the product triacylglyceride leaves back through the lateral gate.]]
-
=== Acyl-CoA Binding ===
+
=== Oleoyl-CoA Binding ===
<scene name='87/877512/Dgat_aligned2/16'>His415 conformational change</scene>
<scene name='87/877512/Dgat_aligned2/16'>His415 conformational change</scene>
Line 57: Line 57:
[[Image:DGAT_INHIBITOR.png|400 px|right|thumb|'''Figure 4: DGAT Inhibitor AZD7687''' Shown is the structure of AZD7687, a known inhibitor of DGAT.]]
[[Image:DGAT_INHIBITOR.png|400 px|right|thumb|'''Figure 4: DGAT Inhibitor AZD7687''' Shown is the structure of AZD7687, a known inhibitor of DGAT.]]
-
 
-
<scene name='87/877512/Mutation/4'>Point Mutation</scene>
 
-
<scene name='87/877512/Cple/2'>CPLE</scene>
+
Obesity and nonalcoholic fatty liver disease (([https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/symptoms-causes/syc-20354567 NAFLD])) result from an accumulation of triglycerides within the body. Recently, DGAT has become a therapeutic target for obesity and nonalcoholic fatty liver disease in order to reduce triglyceride storage within the body. Different inhibitors have been created, such as AstraZeneca’s direct [https://www.apexbt.com/azd7687.html inhibitor] AZD7687, shown in Figure 4 <ref name="Denison">PMID: 24118885</ref>. AZD7687 has an EC50 value 0.44 µmol/L, showing that it binds with high affinity at a low concentration of DGAT. However, while triglyceride accumulation decreased, negative side effects did occur, such as diarrhea and other adverse GI symptoms.
-
+
Additionally, congenital protein-losing enteropathy (([https://www.uptodate.com/contents/protein-losing-gastroenteropathy PLE])) is linked to DGAT mutations. PLE is a GI disorder that causes malabsorption of fat and a deficiency in fat-soluble vitamins. Patients in a congenital PLE case study exhibited a homozygous missense Leu295Pro mutation within the MBOAT core of their DGAT enzymes <ref name="Stephen">PMID: 26883093</ref>. <scene name='87/877512/Mutation/4'>Leu295</scene> is located within the MBOAT core active site on TM5. While the Leu295 is not near the catalytic residues His415 and Glu416, the <scene name='88/880292/Cple/2'>Leu295Pro</scene> mutation will disrupt the overall active site. Proline is an alpha helix breaker because it causes steric hindrance within the backbone of the helix turn. It is hypothesized that this mutation breaks this helix in the MBOAT core and greatly reduces its enzymatic activity and ability to make triacylglycerides. Without proper DGAT function to produce triacylglycerides, there is a decrease in albumin, which is a protein that helps prevent fluid from leaking out of the liver and blood vessels. This decrease in albumin then leads to decreased efficiency in nutrient transport and fat absorption.
-
Obesity and nonalcoholic fatty liver disease ([https://www.mayoclinic.org/diseases-conditions/nonalcoholic-fatty-liver-disease/symptoms-causes/syc-20354567 NAFLD]) result from an accumulation of triglycerides within the body. Recently, DGAT has become a therapeutic target for obesity and nonalcoholic fatty liver disease in order to reduce triglyceride storage within the body. Different inhibitors have been created, such as AstraZeneca’s direct [https://www.apexbt.com/azd7687.html inhibitor] AZD7687, shown in Figure 4 <ref name="Denison">PMID: 24118885</ref>. AZD7687 has an EC50 value 0.44 µmol/L, showing that it binds with high affinity at a low concentration of DGAT. However, while triglyceride accumulation decreased, negative side effects did occur, such as diarrhea and other adverse GI symptoms.
+
-
Additionally, congenital protein-losing enteropathy ([https://www.uptodate.com/contents/protein-losing-gastroenteropathy PLE]) is linked to DGAT mutations. PLE is a GI disorder that causes malabsorption of fat and a deficiency in fat-soluble vitamins. Patients in a congenital PLE case study exhibited a homozygous missense Leu295Pro mutation within the MBOAT core of their DGAT enzymes <ref name="Stephen">PMID: 26883093</ref>. Proline will disrupt an alpha helix because it causes steric hindrance within the backbone of the helix turn. It is hypothesized that this mutation breaks this helix in the MBOAT core and greatly reduces its enzymatic activity and ability to make triacylglycerides. Without proper DGAT function to produce triacylglycerides, there is a decrease in albumin, which is a protein that helps prevent fluid from leaking out of the liver and blood vessels. This decrease in albumin then leads to decreased efficiency in nutrient transport and fat absorption.
 
== Relevance ==
== Relevance ==

Revision as of 01:50, 23 April 2021

Diacylglycerol acyltransferase, DGAT, synthesizes triacylglycerides

Shown is the overall structure of Diacylglycerol Acyltransferase (DGAT) with its two substrates Acyl-CoA and Diacylglycerol (DAG) bound, shown in beige as surface.

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 Wang L, Qian H, Nian Y, Han Y, Ren Z, Zhang H, Hu L, Prasad BVV, Laganowsky A, Yan N, Zhou M. Structure and mechanism of human diacylglycerol O-acyltransferase 1. Nature. 2020 May;581(7808):329-332. doi: 10.1038/s41586-020-2280-2. Epub 2020 May, 13. PMID:32433610 doi:http://dx.doi.org/10.1038/s41586-020-2280-2
  2. 2.0 2.1 Sui X, Wang K, Gluchowski NL, Elliott SD, Liao M, Walther TC, Farese RV Jr. Structure and catalytic mechanism of a human triacylglycerol-synthesis enzyme. Nature. 2020 May;581(7808):323-328. doi: 10.1038/s41586-020-2289-6. Epub 2020 May, 13. PMID:32433611 doi:http://dx.doi.org/10.1038/s41586-020-2289-6
  3. 3.0 3.1 3.2 3.3 Ma D, Wang Z, Merrikh CN, Lang KS, Lu P, Li X, Merrikh H, Rao Z, Xu W. Crystal structure of a membrane-bound O-acyltransferase. Nature. 2018 Oct;562(7726):286-290. doi: 10.1038/s41586-018-0568-2. Epub 2018 Oct, 3. PMID:30283133 doi:http://dx.doi.org/10.1038/s41586-018-0568-2
  4. 4.0 4.1 Denison H, Nilsson C, Lofgren L, Himmelmann A, Martensson G, Knutsson M, Al-Shurbaji A, Tornqvist H, Eriksson JW. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial. Diabetes Obes Metab. 2014 Apr;16(4):334-43. doi: 10.1111/dom.12221. Epub 2013 Oct, 31. PMID:24118885 doi:http://dx.doi.org/10.1111/dom.12221
  5. 5.0 5.1 Stephen J, Vilboux T, Haberman Y, Pri-Chen H, Pode-Shakked B, Mazaheri S, Marek-Yagel D, Barel O, Di Segni A, Eyal E, Hout-Siloni G, Lahad A, Shalem T, Rechavi G, Malicdan MC, Weiss B, Gahl WA, Anikster Y. Congenital protein losing enteropathy: an inborn error of lipid metabolism due to DGAT1 mutations. Eur J Hum Genet. 2016 Aug;24(9):1268-73. doi: 10.1038/ejhg.2016.5. Epub 2016 Feb , 17. PMID:26883093 doi:http://dx.doi.org/10.1038/ejhg.2016.5
  6. Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs. 2020 Jan;29(1):63-71. doi:, 10.1080/13543784.2020.1705277. Epub 2019 Dec 19. PMID:31847611 doi:http://dx.doi.org/10.1080/13543784.2020.1705277
  7. Scott SA, Mathews TP, Ivanova PT, Lindsley CW, Brown HA. Chemical modulation of glycerolipid signaling and metabolic pathways. Biochim Biophys Acta. 2014 Aug;1841(8):1060-84. doi:, 10.1016/j.bbalip.2014.01.009. Epub 2014 Jan 15. PMID:24440821 doi:http://dx.doi.org/10.1016/j.bbalip.2014.01.009

Student Contributors

  • Betsy Johns
  • Elise Wang
  • Tyler Bihasa

Proteopedia Page Contributors and Editors (what is this?)

Betsy Johns

Personal tools